You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九洲藥業(603456.SH):MPP授予的奈瑪特韋的仿製藥原料藥非獨家許可
格隆匯 03-20 15:46

格隆匯3月20日丨九洲藥業(603456.SH)公佈,MPP("藥品專利池組織")授予公司使用相關專利和專有技術生產在研新冠治療口服藥物PAXLOVID(Nirmatrelvir 和 Ritonavir)中 Nirmatrelvir(奈瑪特韋)的仿製藥原料藥(以下簡稱"合作藥物"),並在區域內(印度、印度尼西亞、埃及等 95箇中低收入國家或公共採購機構)商業化合作藥物及相關權利的非獨家許可。

公吿稱,PAXLOVID是一款由輝瑞公司開發的口服小分子新冠病毒治療藥物,用於治療成人伴有進展為重症高風險因素的輕至中度新型冠狀病毒肺炎患者。

截至公吿日,於全球範圍內,PAXLOVID相繼獲得(其中主要包括)美國食品藥品監督管理局(美國 FDA)的緊急使用授權(EUA)、歐洲藥品管理局(EMA)的有條件批准、日本厚生勞動省的緊急特例批准、中國國家藥品監督管理局的應急附條件批准等。

根據 MPP 官網 (https://medicinespatentpool.org/ org/)公佈的信息,包括九洲藥業在內,MPP 目前已向全球 35 家藥企授予非獨家的生產、商業化以及相關權利的許可,以向全球 95 箇中低收入國家供應 PAXLOVID

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account